\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ significant\\ physical\\ exam\\ and\\ laboratory\\ findings\\.\ \(0\)\
\-\ laparoscopic\\ left\\ partial\\ nephrectomy\\ preformed\\ along\\ with\\ follow\\-up\\ imaging\\.\ \(0\)\
\-\ exophytic\\ mass\\ off\\ inferior\\ pole\\ of\\ left\\ kidney\\.\\ \\ the\\ solid\\,\\ heterogenous\\ mass\\ measures\\ 2\\.7\\ cm\\ in\\ diameter\\ and\\ disturbs\\ the\\ renal\\ contour\\.\\ \\ the\\ remainder\\ of\\ the\\ left\\ and\\ right\\ kidneys\\ is\\ normal\\.\\ \\ no\\ renal\\ vein\\ or\\ inferior\\ vena\\ cava\\ thromboses\\ are\\ present\\.\\ \\ there\\ is\\ no\\ adenopathy\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\.\ \(13\)\
\-\ 1\\.\\ \\ renal\\ cell\\ carcinoma\ \(0\)\
\-\ 2\\.\\ \\ renal\\ metastasis\ \(0\)\
\-\ 3\\.\\ \\ renal\\ adenoma\ \(0\)\
\-\ 4\\.\\ \\ oncocytoma\ \(0\)\
\-\ 5\\.\\ \\ renal\\ lymphoma\ \(0\)\
\-\ 6\\.\\ \\ renal\\ angiomyolipoma\ \(0\)\
\-\ 7\\.\\ \\ acute\\ focal\\ pyelonephritis\ \(0\)\
\-\ history\\ of\\ right\\ upper\\ quadrant\\ pain\\ for\\ the\\ past\\ two\\ weeks\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\\,\\ the\\ most\\ common\\ primary\\ tumor\\ of\\ the\\ kidney\\,\\ is\\ found\\ incidentally\\ in\\ many\\ patients\\ with\\ the\\ widespread\\ use\\ of\\ cross\\-sectional\\ imaging\\.\\ \\ in\\ fact\\,\\ as\\ many\\ as\\ one\\-half\\ of\\ renal\\ cell\\ carcinomas\\ are\\ discovered\\ incidentally\\ at\\ early\\ stages\\ when\\ they\\ are\\ asymptomatic\\.\\ \\ ct\\ has\\ also\\ played\\ an\\ essential\\ role\\ in\\ staging\\ renal\\ cell\\ carcinoma\\ in\\ order\\ to\\ guide\\ prognosis\\ and\\ surgical\\ planning\\.\\ \\ the\\ patient\\ in\\ this\\ case\\ underwent\\ partial\\ nephrectomy\\ for\\ his\\ renal\\ cell\\ carcinoma\\.\\ \\ as\\ a\\ result\\,\\ this\\ case\\ generates\\ several\\ interesting\\ questions\\.\\ \\ what\\ is\\ the\\ standard\\ protocol\\ for\\ staging\\ renal\\ cell\\ carcinoma\\ with\\ ct\\?\\ \\ what\\ staging\\ systems\\ exist\\ for\\ renal\\ cell\\ carcinoma\\ and\\ what\\ are\\ their\\ differences\\?\\ \\ finally\\,\\ what\\ factors\\ determine\\ the\\ use\\ of\\ radical\\ nephrectomy\\ versus\\ nephron\\-sparing\\ surgical\\ techniques\\?\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ once\\ a\\ renal\\ cell\\ carcinoma\\ is\\ suspected\\ incidentally\\,\\ there\\ is\\ a\\ standard\\ protocol\\ for\\ work\\-up\\ using\\ ct\\.\\ \\ first\\,\\ an\\ unenhanced\\ ct\\ is\\ preformed\\ to\\ use\\ as\\ a\\ baseline\\ once\\ intravenous\\ contrast\\ material\\ is\\ administered\\.\\ \\ due\\ to\\ a\\ significant\\ vascular\\ supply\\,\\ renal\\ cell\\ carcinomas\\ enhance\\ following\\ administration\\ of\\ contrast\\.\\ \\ 12\\ hu\\ of\\ enhancement\\ suggest\\ possible\\ malignancy\\.\\ \\ following\\ the\\ administration\\ of\\ contrast\\,\\ images\\ are\\ obtained\\ during\\ the\\ corticomedullary\\ phase\\,\\ nephrographic\\ phase\\,\\ and\\ excretory\\ phase\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \ \(1250\)\
\-\ the\\ corticomedullary\\ phase\\ occurs\\ between\\ 25\\ and\\ 70\\ seconds\\ after\\ injection\\ and\\ primarily\\ enhances\\ the\\ renal\\ cortex\\.\\ \\ while\\ not\\ perfect\\ for\\ detecting\\ small\\ lesions\\,\\ this\\ phase\\ can\\ aid\\ in\\ diagnosing\\ venous\\ extension\\ of\\ the\\ tumor\\.\\ \\ the\\ nephrographic\\ phase\\,\\ which\\ occurs\\ between\\ 80\\ and\\ 180\\ seconds\\ following\\ injection\\,\\ is\\ best\\ for\\ detecting\\ renal\\ masses\\ and\\ analyzing\\ indeterminate\\ lesions\\.\\ \\ finally\\,\\ the\\ excretory\\ phase\\ begins\\ 180\\ seconds\\ following\\ injection\\ and\\ helps\\ evaluate\\ the\\ collecting\\ system\\,\\ as\\ well\\ as\\ the\\ calices\\ and\\ renal\\ pelvis\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \ \(1866\)\
\-\ \\ renal\\ cell\\ carcinoma\\ has\\ two\\ potential\\ staging\\ systems\\:\\ the\\ robson\\ classification\\ and\\ the\\ tmn\\ classification\\.\\ \\ ct\\ is\\ reported\\ to\\ be\\ 91\\%\\ accurate\\ in\\ staging\\ renal\\ cell\\ carcinoma\\.\\ \\ the\\ tmn\\ classification\\ is\\ considered\\ more\\ precise\\ because\\ of\\ its\\ clear\\ definition\\ of\\ the\\ anatomic\\ extent\\ of\\ the\\ tumor\\.\\ \\ with\\ respect\\ to\\ the\\ tmn\\ classification\\,\\ t1\\ is\\ reserved\\ for\\ tumors\\ less\\ than\\ 7\\ cm\\ and\\ t2\\ for\\ tumors\\ greater\\ than\\ 7\\ cm\\.\\ \\ t3\\ is\\ broken\\ down\\ into\\ three\\ groups\\ based\\ on\\ tumor\\ position\\.\\ \\ t3a\\ indicates\\ spread\\ to\\ the\\ perinephric\\ fat\\.\\ \\ t3b\\ indicates\\ that\\ the\\ tumor\\ is\\ present\\ in\\ the\\ renal\\ vein\\ only\\.\\ \\ t3c\\ describes\\ a\\ tumor\\ in\\ the\\ infradiaphragmatic\\ ivc\\.\\ \\ t4a\\ and\\ t4b\\ describe\\ tumors\\ with\\ direct\\ invasion\\ of\\ adjacent\\ organs\\ and\\ presence\\ in\\ the\\ supradiaphragmatic\\ ivc\\,\\ respectively\\.\\ \\ n1\\-3\\ are\\ reserved\\ for\\ regional\\ lymph\\ node\\ metastases\\ and\\ m1a\\-d\\ for\\ distant\\ metastases\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \ \(2733\)\
\-\ the\\ robson\\ classification\\ is\\ staged\\ i\\-iv\\.\\ \\ i\\ is\\ given\\ to\\ a\\ tumor\\ confined\\ within\\ the\\ renal\\ capsule\\.\\ \\ ii\\ indicates\\ spread\\ to\\ the\\ perinephric\\ fat\\.\\ \\ iiia\\ describes\\ the\\ presence\\ of\\ a\\ venous\\ thrombus\\,\\ whereas\\ iiib\\ describes\\ regional\\ lymph\\ node\\ metastases\\.\\ \\ iva\\ indicates\\ direct\\ invasion\\ of\\ adjacent\\ organs\\ and\\ ivb\\ indicates\\ distant\\ metastases\\.\\ \\ an\\ important\\ downfall\\ of\\ the\\ robson\\ classification\\ is\\ that\\ it\\ uses\\ stage\\ iii\\ to\\ describe\\ both\\ patients\\ with\\ venous\\ extension\\ alone\\ and\\ patients\\ with\\ regional\\ lymph\\ node\\ metastases\\.\\ \\ the\\ treatment\\ for\\ these\\ two\\ groups\\ of\\ patients\\ varies\\ significantly\\.\\ \\ venous\\ extension\\ of\\ the\\ tumor\\ can\\ be\\ treated\\ surgically\\,\\ whereas\\ lymph\\ node\\ metastases\\ indicate\\ a\\ need\\ for\\ palliative\\ therapy\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \ \(1866\)\
\-\ due\\ to\\ the\\ rapid\\ increase\\ in\\ incidental\\ discovery\\ of\\ renal\\ cell\\ carcinoma\\,\\ many\\ tumors\\ are\\ small\\ in\\ size\\ and\\ early\\-stage\\.\\ \\ therefore\\,\\ nephron\\-sparing\\ surgery\\ is\\ often\\ an\\ option\\.\\ \\ the\\ procedure\\ consists\\ of\\ excision\\ of\\ the\\ renal\\ tumor\\ and\\ obtaining\\ 0\\.5\\ cm\\ margins\\ of\\ normal\\ renal\\ tissue\\ and\\ preserving\\ the\\ largest\\ amount\\ of\\ functioning\\ renal\\ parenchyma\\.\\ \\ this\\ procedure\\ is\\ particularly\\ desirable\\ when\\ radical\\ nephrectomy\\ would\\ lead\\ to\\ dialysis\\.\\ \\ therefore\\,\\ it\\ is\\ indicated\\ in\\ patients\\ with\\ a\\ solitary\\ functioning\\ kidney\\,\\ compromised\\ renal\\ function\\,\\ or\\ bilateral\\ tumors\\.\\ \\ in\\ addition\\,\\ data\\ indicates\\ that\\ small\\ \\<4\\ cm\\ in\\ diameter\\ lesions\\,\\ which\\ are\\ polar\\,\\ cortical\\,\\ and\\ a\\ safe\\ distance\\ away\\ from\\ the\\ renal\\ hilum\\ and\\ collecting\\ systems\\,\\ have\\ similar\\ survival\\ rates\\ for\\ the\\ nephron\\-sparing\\ procedure\\ and\\ radical\\ nephrectomy\\.\\ \\ the\\ size\\ and\\ position\\ of\\ the\\ patient\\â\\€\\™s\\ tumor\\ in\\ this\\ case\\ made\\ him\\ a\\ good\\ candidate\\ for\\ the\\ nephron\\-sparing\\ procedure\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.08780281949797643\ \(0\)\
\-\ nephron\\-sparing\\:\\ 0\\.04158263407531367\ \(0\)\
\-\ indicates\\:\\ 0\\.03559902445788847\ \(0\)\
\-\ cell\\:\\ 0\\.03538576562565958\ \(0\)\
\-\ classification\\:\\ 0\\.034554430126713484\ \(0\)\
\-\ phase\\:\\ 0\\.033181715977108846\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03141651458746997\ \(0\)\
\-\ staging\\:\\ 0\\.029031238949621885\ \(0\)\
\-\ tmn\\:\\ 0\\.028734803927145825\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.02856855253782062\ \(0\)\
\-\ robson\\:\\ 0\\.027300375478649958\ \(0\)\
\-\ metastases\\:\\ 0\\.025830654127662625\ \(0\)\
\-\ tumor\\:\\ 0\\.02349330544352372\ \(0\)\
\-\ seconds\\:\\ 0\\.02160660927900102\ \(0\)\
\-\ what\\:\\ 0\\.021280440239444944\ \(0\)\
\-\ nephrographic\\:\\ 0\\.019156535951430548\ \(0\)\
\-\ regional\\:\\ 0\\.01915443764966159\ \(0\)\
\-\ radical\\:\\ 0\\.018926117409788105\ \(0\)\
\-\ tumors\\:\\ 0\\.018925214373057202\ \(0\)\
\-\ node\\:\\ 0\\.01844454549777391\ \(0\)\
\-\ describes\\:\\ 0\\.018412501808923138\ \(0\)\
\-\ 180\\:\\ 0\\.018200250319099973\ \(0\)\
\-\ procedure\\:\\ 0\\.016882436137436552\ \(0\)\
\-\ lymph\\:\\ 0\\.01627142645728607\ \(0\)\
\-\ systems\\:\\ 0\\.01605726051279638\ \(0\)\
\-\ excretory\\:\\ 0\\.015609183600543109\ \(0\)\
\-\ preformed\\:\\ 0\\.0149306881466474\ \(0\)\
\-\ venous\\:\\ 0\\.014631064238005325\ \(0\)\
\-\ corticomedullary\\:\\ 0\\.014567125222526508\ \(0\)\
\-\ injection\\:\\ 0\\.014105676957538433\ \(0\)\
\-\ incidentally\\:\\ 0\\.013704750004801394\ \(0\)\
\-\ cm\\:\\ 0\\.013513892204109586\ \(0\)\
\-\ reserved\\:\\ 0\\.013396283509522048\ \(0\)\
\-\ detecting\\:\\ 0\\.013295907060421113\ \(0\)\
\-\ is\\:\\ 0\\.013261574961903907\ \(0\)\
\-\ functioning\\:\\ 0\\.013107127089492961\ \(0\)\
\-\ patients\\:\\ 0\\.013039944571733644\ \(0\)\
\-\ describe\\:\\ 0\\.013018116881986248\ \(0\)\
\-\ carcinomas\\:\\ 0\\.012932344136300221\ \(0\)\
\-\ groups\\:\\ 0\\.012932344136300221\ \(0\)\
\-\ for\\:\\ 0\\.012896960176463121\ \(0\)\
\-\ perinephric\\:\\ 0\\.012769625099774392\ \(0\)\
\-\ many\\:\\ 0\\.012425283664766825\ \(0\)\
\-\ finally\\:\\ 0\\.012212104396792718\ \(0\)\
\-\ whereas\\:\\ 0\\.011976058503969645\ \(0\)\
\-\ use\\:\\ 0\\.011948487435294704\ \(0\)\
\-\ \\?\\:\\ 0\\.011797922761643303\ \(0\)\
\-\ distant\\:\\ 0\\.011761502423295761\ \(0\)\
\-\ organs\\:\\ 0\\.011564847685231961\ \(0\)\
\-\ following\\:\\ 0\\.011439989419345039\ \(0\)\
\-\ are\\:\\ 0\\.010989376155939638\ \(0\)\
\-\ protocol\\:\\ 0\\.01083964792167545\ \(0\)\
\-\ extension\\:\\ 0\\.010791252315501133\ \(0\)\
\-\ ivc\\:\\ 0\\.010737826761615997\ \(0\)\
\-\ kidney\\:\\ 0\\.010649941468337299\ \(0\)\
\-\ disturbs\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ t4a\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ t4b\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ n1\\-3\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ m1a\\-d\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ downfall\\:\\ 0\\.010395658518828418\ \(0\)\
\-\ standard\\:\\ 0\\.01031336596102873\ \(0\)\
\-\ once\\:\\ 0\\.01031336596102873\ \(0\)\
\-\ collecting\\:\\ 0\\.01028578096158724\ \(0\)\
\-\ \\,\\:\\ 0\\.009896240602636684\ \(0\)\
\-\ spread\\:\\ 0\\.009748554709533674\ \(0\)\
\-\ invasion\\:\\ 0\\.009705278439089814\ \(0\)\
\-\ generates\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ perfect\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ analyzing\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ t3a\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ t3b\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ t3c\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ early\\-stage\\:\\ 0\\.009578267975715274\ \(0\)\
\-\ direct\\:\\ 0\\.009519799365223982\ \(0\)\
\-\ therefore\\:\\ 0\\.009519799365223982\ \(0\)\
\-\ as\\:\\ 0\\.00914559556057166\ \(0\)\
\-\ calices\\:\\ 0\\.009100125159549987\ \(0\)\
\-\ supradiaphragmatic\\:\\ 0\\.009100125159549987\ \(0\)\
\-\ i\\-iv\\:\\ 0\\.009100125159549987\ \(0\)\
\-\ thromboses\\:\\ 0\\.008760877432602131\ \(0\)\
\-\ played\\:\\ 0\\.008760877432602131\ \(0\)\
\-\ infradiaphragmatic\\:\\ 0\\.008760877432602131\ \(0\)\
\-\ two\\:\\ 0\\.00865801145383021\ \(0\)\
\-\ iiia\\:\\ 0\\.00849773645227877\ \(0\)\
\-\ iva\\:\\ 0\\.00849773645227877\ \(0\)\
\-\ ivb\\:\\ 0\\.00849773645227877\ \(0\)\
\-\ preserving\\:\\ 0\\.00849773645227877\ \(0\)\
\-\ desirable\\:\\ 0\\.00849773645227877\ \(0\)\
\-\ diameter\\:\\ 0\\.008479157072849465\ \(0\)\
\-\ in\\:\\ 0\\.008447821830641902\ \(0\)\
\-\ position\\:\\ 0\\.008391563801742257\ \(0\)\
\-\ administration\\:\\ 0\\.008367123266281062\ \(0\)\
\-\ occurs\\:\\ 0\\.008271817751333238\ \(0\)\
\-\ one\\-half\\:\\ 0\\.008100953154376396\ \(0\)\
\-\ polar\\:\\ 0\\.008100953154376396\ \(0\)\
\-\ lesions\\:\\ 0\\.00809278481017906\ \(0\)\
\-\ partial\\:\\ 0\\.008059801232190437\ \(0\)\
\-\ staged\\:\\ 0\\.007943486889488987\ \(0\)\
\-\ iiib\\:\\ 0\\.007943486889488987\ \(0\)\
\-\ 7\\:\\ 0\\.007722299242471867\ \(0\)\
\-\ cross\\-sectional\\:\\ 0\\.007680345909165627\ \(0\)\
\-\ differences\\:\\ 0\\.007680345909165627\ \(0\)\
\-\ the\\:\\ 0\\.007662401392771713\ \(0\)\
\-\ precise\\:\\ 0\\.0074653440733237\ \(0\)\
\-\ questions\\:\\ 0\\.007370954087859624\ \(0\)\
\-\ presence\\:\\ 0\\.007315532119002662\ \(0\)\
\-\ vein\\:\\ 0\\.007292295570788012\ \(0\)\
\-\ guide\\:\\ 0\\.007283562611263254\ \(0\)\
\-\ broken\\:\\ 0\\.007202203093000339\ \(0\)\
\-\ safe\\:\\ 0\\.007202203093000339\ \(0\)\
\-\ discovery\\:\\ 0\\.007126096346375845\ \(0\)\
\-\ indeterminate\\:\\ 0\\.007054605047064012\ \(0\)\
\-\ ct\\:\\ 0\\.007047780975188933\ \(0\)\
\-\ uses\\:\\ 0\\.006987201257158412\ \(0\)\
\-\ compromised\\:\\ 0\\.006987201257158412\ \(0\)\
\-\ small\\:\\ 0\\.006964299355121882\ \(0\)\
\-\ exist\\:\\ 0\\.006923442741509502\ \(0\)\
\-\ 91\\:\\ 0\\.006923442741509502\ \(0\)\
\-\ inferior\\:\\ 0\\.006838010286224204\ \(0\)\
\-\ obtaining\\:\\ 0\\.006805419795097965\ \(0\)\
\-\ contrast\\:\\ 0\\.006766895118424193\ \(0\)\
\-\ size\\:\\ 0\\.0067567827155159705\ \(0\)\
\-\ widespread\\:\\ 0\\.006750561286094555\ \(0\)\
\-\ 2\\.7\\:\\ 0\\.006698141754761024\ \(0\)\
\-\ case\\:\\ 0\\.006613812852124779\ \(0\)\
\-\ helps\\:\\ 0\\.006599814385729124\ \(0\)\
\-\ varies\\:\\ 0\\.006599814385729124\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.006553563544746481\ \(0\)\
\-\ accurate\\:\\ 0\\.006553563544746481\ \(0\)\
\-\ planning\\:\\ 0\\.006509058440993124\ \(0\)\
\-\ hu\\:\\ 0\\.006509058440993124\ \(0\)\
\-\ t3\\:\\ 0\\.006509058440993124\ \(0\)\
\-\ diagnosing\\:\\ 0\\.006424790794787764\ \(0\)\
\-\ respect\\:\\ 0\\.006424790794787764\ \(0\)\
\-\ between\\:\\ 0\\.006387961170340197\ \(0\)\
\-\ essential\\:\\ 0\\.006384812549887196\ \(0\)\
\-\ definition\\:\\ 0\\.006384812549887196\ \(0\)\
\-\ adjacent\\:\\ 0\\.006372255292769498\ \(0\)\
\-\ aid\\:\\ 0\\.0063461453059921605\ \(0\)\
\-\ dialysis\\:\\ 0\\.0063087058032627015\ \(0\)\
\-\ laparoscopic\\:\\ 0\\.006272418469929266\ \(0\)\
\-\ begins\\:\\ 0\\.006272418469929266\ \(0\)\
\-\ 0\\.5\\:\\ 0\\.0062372145039508685\ \(0\)\
\-\ unenhanced\\:\\ 0\\.0062030310878267506\ \(0\)\
\-\ candidate\\:\\ 0\\.0062030310878267506\ \(0\)\
\-\ exophytic\\:\\ 0\\.006137500602974379\ \(0\)\
\-\ palliative\\:\\ 0\\.006137500602974379\ \(0\)\
\-\ fat\\:\\ 0\\.00612951019547555\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.006075420728581193\ \(0\)\
\-\ confined\\:\\ 0\\.006075420728581193\ \(0\)\
\-\ distance\\:\\ 0\\.006075420728581193\ \(0\)\
\-\ hilum\\:\\ 0\\.006075420728581193\ \(0\)\
\-\ stages\\:\\ 0\\.0060455648229393415\ \(0\)\
\-\ techniques\\:\\ 0\\.006016446176016734\ \(0\)\
\-\ role\\:\\ 0\\.005960281023906763\ \(0\)\
\-\ interesting\\:\\ 0\\.005960281023906763\ \(0\)\
\-\ baseline\\:\\ 0\\.005960281023906763\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.005880751211647881\ \(0\)\
\-\ away\\:\\ 0\\.005855390120585424\ \(0\)\
\-\ rates\\:\\ 0\\.005855390120585424\ \(0\)\
\-\ administered\\:\\ 0\\.005806247789924376\ \(0\)\
\-\ respectively\\:\\ 0\\.005806247789924376\ \(0\)\
\-\ when\\:\\ 0\\.005772007635886806\ \(0\)\
\-\ indicate\\:\\ 0\\.005713710507564123\ \(0\)\
\-\ largest\\:\\ 0\\.005713710507564123\ \(0\)\
\-\ work\\-up\\:\\ 0\\.0056916678978799805\ \(0\)\
\-\ this\\:\\ 0\\.005667082625672955\ \(0\)\
\-\ option\\:\\ 0\\.005627909382231071\ \(0\)\
\-\ a\\:\\ 0\\.005612261346489641\ \(0\)\
\-\ supply\\:\\ 0\\.0056074002516746215\ \(0\)\
\-\ an\\:\\ 0\\.005573890869267593\ \(0\)\
\-\ to\\:\\ 0\\.005539798576501001\ \(0\)\
\-\ consists\\:\\ 0\\.005528754762879017\ \(0\)\
\-\ him\\:\\ 0\\.005528754762879017\ \(0\)\
\-\ and\\:\\ 0\\.00551914404367651\ \(0\)\
\-\ capsule\\:\\ 0\\.005455027926816122\ \(0\)\
\-\ alone\\:\\ 0\\.005455027926816122\ \(0\)\
\-\ data\\:\\ 0\\.005455027926816122\ \(0\)\
\-\ significant\\:\\ 0\\.005419450827958074\ \(0\)\
\-\ survival\\:\\ 0\\.005402608395482593\ \(0\)\
\-\ due\\:\\ 0\\.0053780121531906595\ \(0\)\
\-\ 7\\.\\:\\ 0\\.005368913380807998\ \(0\)\
\-\ vena\\:\\ 0\\.00533615446087041\ \(0\)\
\-\ cava\\:\\ 0\\.005304281026450693\ \(0\)\
\-\ fact\\:\\ 0\\.005304281026450693\ \(0\)\
\-\ primarily\\:\\ 0\\.005288661655283216\ \(0\)\
\-\ than\\:\\ 0\\.005280775601222344\ \(0\)\
\-\ that\\:\\ 0\\.0052216299359392334\ \(0\)\
\-\ particularly\\:\\ 0\\.005199055632903591\ \(0\)\
\-\ heterogenous\\:\\ 0\\.005170638708871679\ \(0\)\
\-\ significantly\\:\\ 0\\.005156682980514365\ \(0\)\
\-\ determine\\:\\ 0\\.005102455252634857\ \(0\)\
\-\ surgically\\:\\ 0\\.005102455252634857\ \(0\)\
\-\ anatomic\\:\\ 0\\.005089279190608765\ \(0\)\
\-\ thrombus\\:\\ 0\\.005089279190608765\ \(0\)\
\-\ rapid\\:\\ 0\\.005089279190608765\ \(0\)\
\-\ order\\:\\ 0\\.005050611946713728\ \(0\)\
\-\ need\\:\\ 0\\.005025520674959856\ \(0\)\
\-\ intravenous\\:\\ 0\\.0050009521762536735\ \(0\)\
\-\ extent\\:\\ 0\\.0050009521762536735\ \(0\)\
\-\ solitary\\:\\ 0\\.0050009521762536735\ \(0\)\
\-\ discovered\\:\\ 0\\.004965033299502838\ \(0\)\
\-\ 6\\.\\:\\ 0\\.0048963199644509806\ \(0\)\
\-\ contour\\:\\ 0\\.00488524715743466\ \(0\)\
\-\ enhance\\:\\ 0\\.004874277354766837\ \(0\)\
\-\ potential\\:\\ 0\\.004852639219544907\ \(0\)\
\-\ 70\\:\\ 0\\.004841967243695949\ \(0\)\
\-\ lead\\:\\ 0\\.004831390981923824\ \(0\)\
\-\ versus\\:\\ 0\\.004790009708561478\ \(0\)\
\-\ prognosis\\:\\ 0\\.004779887369302762\ \(0\)\
\-\ enhances\\:\\ 0\\.004759899682611991\ \(0\)\
\-\ remainder\\:\\ 0\\.004750031463660911\ \(0\)\
\-\ 80\\:\\ 0\\.004740245139586977\ \(0\)\
\-\ iii\\:\\ 0\\.004730539362303351\ \(0\)\
\-\ imaging\\:\\ 0\\.004721872227489629\ \(0\)\
\-\ pole\\:\\ 0\\.004692495892706392\ \(0\)\
\-\ kidneys\\:\\ 0\\.00463763738370298\ \(0\)\
\-\ off\\:\\ 0\\.004602433417724583\ \(0\)\
\-\ margins\\:\\ 0\\.004576703409004489\ \(0\)\
\-\ can\\:\\ 0\\.004571279133181768\ \(0\)\
\-\ present\\:\\ 0\\.004551907438518115\ \(0\)\
\-\ it\\:\\ 0\\.004530302793709945\ \(0\)\
\-\ factors\\:\\ 0\\.004526868728238117\ \(0\)\
\-\ important\\:\\ 0\\.004526868728238117\ \(0\)\
\-\ material\\:\\ 0\\.004502719516748094\ \(0\)\
\-\ adenopathy\\:\\ 0\\.00448689048333755\ \(0\)\
\-\ their\\:\\ 0\\.004410783736713056\ \(0\)\
\-\ using\\:\\ 0\\.00437449640337962\ \(0\)\
\-\ indicated\\:\\ 0\\.0043602884570162065\ \(0\)\
\-\ 5\\.\\:\\ 0\\.004346249656890831\ \(0\)\
\-\ ii\\:\\ 0\\.004346249656890831\ \(0\)\
\-\ suspected\\:\\ 0\\.004339292437401222\ \(0\)\
\-\ down\\:\\ 0\\.0043254999376804775\ \(0\)\
\-\ measures\\:\\ 0\\.00431186689239619\ \(0\)\
\-\ cortex\\:\\ 0\\.00431186689239619\ \(0\)\
\-\ good\\:\\ 0\\.00431186689239619\ \(0\)\
\-\ stage\\:\\ 0\\.004298389656755126\ \(0\)\
\-\ suggest\\:\\ 0\\.004291708362491355\ \(0\)\
\-\ parenchyma\\:\\ 0\\.004291708362491355\ \(0\)\
\-\ function\\:\\ 0\\.004271888647495622\ \(0\)\
\-\ addition\\:\\ 0\\.004271888647495622\ \(0\)\
\-\ best\\:\\ 0\\.004239578536424733\ \(0\)\
\-\ surgical\\:\\ 0\\.004236372099649654\ \(0\)\
\-\ increase\\:\\ 0\\.004226898357443292\ \(0\)\
\-\ adenoma\\:\\ 0\\.004208130131846712\ \(0\)\
\-\ amount\\:\\ 0\\.004208130131846712\ \(0\)\
\-\ i\\:\\ 0\\.00416546544248645\ \(0\)\
\-\ excision\\:\\ 0\\.004135908875666619\ \(0\)\
\-\ 12\\:\\ 0\\.004124290601559295\ \(0\)\
\-\ 25\\:\\ 0\\.004073380021529567\ \(0\)\
\-\ evaluate\\:\\ 0\\.004073380021529567\ \(0\)\
\-\ considered\\:\\ 0\\.004067856614321517\ \(0\)\
\-\ solid\\:\\ 0\\.0040192767128612965\ \(0\)\
\-\ made\\:\\ 0\\.004014000438810682\ \(0\)\
\-\ 4\\.\\:\\ 0\\.003967547134906601\ \(0\)\
\-\ system\\:\\ 0\\.003967547134906601\ \(0\)\
\-\ similar\\:\\ 0\\.0039524606355435\ \(0\)\
\-\ malignancy\\:\\ 0\\.0038939736766527306\ \(0\)\
\-\ \\<\\:\\ 0\\.0038892282163936207\ \(0\)\
\-\ result\\:\\ 0\\.003865783203948068\ \(0\)\
\-\ based\\:\\ 0\\.003842795238522359\ \(0\)\
\-\ incidental\\:\\ 0\\.003815788441014476\ \(0\)\
\-\ its\\:\\ 0\\.0038025134946410863\ \(0\)\
\-\ greater\\:\\ 0\\.00378504287461144\ \(0\)\
\-\ has\\:\\ 0\\.0037846697417317876\ \(0\)\
\-\ metastasis\\:\\ 0\\.003772107696108404\ \(0\)\
\-\ which\\:\\ 0\\.003762133460477709\ \(0\)\
\-\ clear\\:\\ 0\\.003725856855125761\ \(0\)\
\-\ laboratory\\:\\ 0\\.003713551575299606\ \(0\)\
\-\ early\\:\\ 0\\.00368532897363495\ \(0\)\
\-\ reported\\:\\ 0\\.0036734373237922308\ \(0\)\
\-\ cortical\\:\\ 0\\.0036734373237922308\ \(0\)\
\-\ pelvis\\:\\ 0\\.0036616643945655996\ \(0\)\
\-\ they\\:\\ 0\\.00363083269632937\ \(0\)\
\-\ would\\:\\ 0\\.0035860458471958603\ \(0\)\
\-\ obtained\\:\\ 0\\.0035823892697450965\ \(0\)\
\-\ of\\:\\ 0\\.0035720504961647397\ \(0\)\
\-\ quadrant\\:\\ 0\\.003546433884417517\ \(0\)\
\-\ because\\:\\ 0\\.0035253753733326034\ \(0\)\
\-\ underwent\\:\\ 0\\.003457778343724315\ \(0\)\
\-\ given\\:\\ 0\\.003454498104382479\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0034479648728074613\ \(0\)\
\-\ less\\:\\ 0\\.0034126650994371253\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.003406358959901046\ \(0\)\
\-\ masses\\:\\ 0\\.003406358959901046\ \(0\)\
\-\ three\\:\\ 0\\.00339696253342796\ \(0\)\
\-\ possible\\:\\ 0\\.003393846956231217\ \(0\)\
\-\ left\\:\\ 0\\.003382447886578708\ \(0\)\
\-\ first\\:\\ 0\\.0033814663146059577\ \(0\)\
\-\ along\\:\\ 0\\.003330252213276552\ \(0\)\
\-\ vascular\\:\\ 0\\.0033040132876458687\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.003278345508775639\ \(0\)\
\-\ several\\:\\ 0\\.0032394962685405515\ \(0\)\
\-\ often\\:\\ 0\\.0032151810713675144\ \(0\)\
\-\ 2\\.\\:\\ 0\\.00320453318608521\ \(0\)\
\-\ past\\:\\ 0\\.003201886169748153\ \(0\)\
\-\ t1\\:\\ 0\\.0031939805851700985\ \(0\)\
\-\ found\\:\\ 0\\.003175737752891642\ \(0\)\
\-\ while\\:\\ 0\\.0031705769337881055\ \(0\)\
\-\ normal\\:\\ 0\\.0031594633363186343\ \(0\)\
\-\ 1\\.\\:\\ 0\\.00314762873384151\ \(0\)\
\-\ be\\:\\ 0\\.0031079168003394554\ \(0\)\
\-\ during\\:\\ 0\\.0030837373230233585\ \(0\)\
\-\ no\\:\\ 0\\.0030440241180559034\ \(0\)\
\-\ only\\:\\ 0\\.0030299665784020466\ \(0\)\
\-\ treated\\:\\ 0\\.0030163335331177582\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.003011823985430962\ \(0\)\
\-\ there\\:\\ 0\\.002999329142606105\ \(0\)\
\-\ primary\\:\\ 0\\.002985122951527944\ \(0\)\
\-\ his\\:\\ 0\\.0029043502684515704\ \(0\)\
\-\ s\\:\\ 0\\.0028900562112200317\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0028799512197989216\ \(0\)\
\-\ focal\\:\\ 0\\.002877940570917927\ \(0\)\
\-\ weeks\\:\\ 0\\.0028599973548362597\ \(0\)\
\-\ t2\\:\\ 0\\.0028521093971112643\ \(0\)\
\-\ 4\\:\\ 0\\.0028077498881828363\ \(0\)\
\-\ mass\\:\\ 0\\.0028029740729895386\ \(0\)\
\-\ enhancement\\:\\ 0\\.002701048073258297\ \(0\)\
\-\ therapy\\:\\ 0\\.002694151882359213\ \(0\)\
\-\ common\\:\\ 0\\.002637107561269336\ \(0\)\
\-\ these\\:\\ 0\\.00262245836315783\ \(0\)\
\-\ both\\:\\ 0\\.0025733490456204262\ \(0\)\
\-\ more\\:\\ 0\\.002520255081736045\ \(0\)\
\-\ acute\\:\\ 0\\.002488065246587848\ \(0\)\
\-\ physical\\:\\ 0\\.0024722939499778754\ \(0\)\
\-\ surgery\\:\\ 0\\.0024469328589154186\ \(0\)\
\-\ bilateral\\:\\ 0\\.0024455397751349576\ \(0\)\
\-\ upper\\:\\ 0\\.0024316987091612245\ \(0\)\
\-\ into\\:\\ 0\\.002397790528254371\ \(0\)\
\-\ tissue\\:\\ 0\\.0023884683826091904\ \(0\)\
\-\ or\\:\\ 0\\.0023620819551030837\ \(0\)\
\-\ \\%\\:\\ 0\\.002350614426115575\ \(0\)\
\-\ most\\:\\ 0\\.0023264565350566936\ \(0\)\
\-\ well\\:\\ 0\\.0022795765954818996\ \(0\)\
\-\ exam\\:\\ 0\\.0022137192688084176\ \(0\)\
\-\ have\\:\\ 0\\.0021821203754305326\ \(0\)\
\-\ findings\\:\\ 0\\.0021448548771108014\ \(0\)\
\-\ right\\:\\ 0\\.002126489879977398\ \(0\)\
\-\ after\\:\\ 0\\.0020849070785485878\ \(0\)\
\-\ treatment\\:\\ 0\\.002039642641038782\ \(0\)\
\-\ patient\\:\\ 0\\.002020263988010349\ \(0\)\
\-\ \\.\\:\\ 0\\.002009407703623374\ \(0\)\
\-\ also\\:\\ 0\\.0019865797095166876\ \(0\)\
\-\ images\\:\\ 0\\.001933094212204427\ \(0\)\
\-\ within\\:\\ 0\\.0019223247740401904\ \(0\)\
\-\ from\\:\\ 0\\.001493438340983741\ \(0\)\
\-\ not\\:\\ 0\\.0014561540940353011\ \(0\)\
\-\ history\\:\\ 0\\.0013917624265413718\ \(0\)\
\-\ at\\:\\ 0\\.001365286736829756\ \(0\)\
\-\ \\:\\:\\ 0\\.0013328712452720106\ \(0\)\
\-\ pain\\:\\ 0\\.0012306700088805832\ \(0\)\
\-\ with\\:\\ 0\\.0011038129819800919\ \(0\)\
\-\ on\\:\\ 0\\.000853645061751684\ \(0\)\
